Kathleen Finneke
Medical · Chicago, ILNPI 1053714576
Payments from drug & device makers
Across 133 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$380
- Sanofi$357
- AstraZeneca$277
- GSK$248
- Regeneron Healthcare Solutions, Inc.$204
- Pharming Healthcare, Inc.$192
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,726100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $380 |
| Sanofi | 20 | $357 |
| AstraZeneca | 15 | $277 |
| GSK | 12 | $248 |
| Regeneron Healthcare Solutions, Inc. | 11 | $204 |
| Pharming Healthcare, Inc. | 5 | $192 |
| Hospira, Inc. | 5 | $120 |
| Tersera Therapeutics LLC | 3 | $87 |
| Genentech USA, Inc. | 4 | $86 |
| Octapharma USA, Inc. | 2 | $86 |
| Blueprint Medicines Corporation | 2 | $68 |
| Boehringer Ingelheim | 4 | $68 |
| CSL Behring | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Kaleo, Inc. | 3 | $60 |
| LEO Pharma Inc. | 2 | $46 |
| Optinose US, Inc. | 3 | $45 |
| Pfizer | 2 | $42 |
| Phadia US Inc. | 2 | $35 |
| Grifols USA, LLC | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Covis Pharma GmbH | 1 | $26 |
| Amgen | 1 | $26 |
| Biocryst US Sales Co., LLC | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUCONEST$114
How this compares
$2,726 in reported general payments places this provider in the 80th percentile of 449 medical providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 15 | $41,096 |
| Montelukast Sodium | 47 | $422 |
Paid to pharmacies, not to this prescriber.
Other medical in Chicago
- Andrea TurekChicago$145K
- Jennifer GarsonChicago$32K
- William KvasnickaChicago$19K
- Brittany WolfeChicago$12K
- Eric KingChicago$9K
- Neema ManappuramChicago$8K
- Robert RadtkeChicago$7K
- Koree RamseyChicago$5K
- Justin OkrayChicago$5K
- Alexis DavidmanChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.